# Richter transformation to classical Hodgkin lymphoma following recurrent disseminated histoplasmosis in chronic lymphocytic leukemia: a Case Report

**Authors:** Delour Haj, Mohamed Said, Talal Al-Assil, Steven Stone, Mohammad Omaira

PMC · DOI: 10.3389/fonc.2026.1714656 · Frontiers in Oncology · 2026-02-16

## TL;DR

A rare case of Richter transformation to Hodgkin lymphoma occurred in a CLL patient with recurring histoplasmosis, highlighting the need for vigilance in managing infections and monitoring for aggressive lymphoma.

## Contribution

This case report highlights the unusual progression of Richter transformation following chronic histoplasmosis in a CLL patient.

## Key findings

- Richter transformation occurred 21 years after initial CLL diagnosis following multiple histoplasmosis reinfections.
- Histoplasmosis recurrences and RT were detected using PET/CT scans and biopsies.
- Treatment with AVD chemotherapy and nivolumab led to recovery despite impaired renal function.

## Abstract

Richter Transformation (RT) is the rare progression of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into a more aggressive lymphoma, occurring in only about 5-10% of cases. RT has a poor prognosis with rapid progression and resistance to standard therapies. PET/CT scans are crucial in detecting RT with increased SUVmax indicating more aggressive disease.

A 65-year-old male with 13q deletion CLL developed three relapses over the course of 13 years from initial CLL diagnosis, and work up of the third relapse revealed disseminated histoplasmosis. He improved with Ibrutinib for CLL and Amphotericin B for histoplasmosis. Four and seven years later, the patient re-presented with histoplasmosis reinfections, confirmed by PET/CT and biopsy, and treated with antifungals for each reinfection. One year later (21 years from initial CLL diagnosis), he presented with malignant hypercalcemia and retroperitoneal lymphadenopathy (LAD) for which biopsy revealed RT to classic Hodgkin’s Lymphoma (cHL). Given his impaired renal function, his treatment regimen included AVD chemotherapy and nivolumab, from which he eventually recovered.

CLL patients are inherently immunocompromised due to hypogammaglobulinemia, increasing their susceptibility to opportunistic infections like histoplasmosis. These infections can recur, be refractory, and may even coincide with RT. This unusual case of RT after chronic disseminated histoplasmosis reinfections involved lymph nodes and eventually hypercalcemia. Vigilant monitoring and patient education on risk avoidance are recommended strategies for mitigating risk of histoplasmosis. Providers may also consider Itraconazole prophylaxis. Further research is warranted to better understand the relationship between chronic opportunistic infections and the oncogenic progressions in CLL patients.

## Linked entities

- **Chemicals:** Ibrutinib (PubChem CID 24821094), Amphotericin B (PubChem CID 1972), Itraconazole (PubChem CID 55283)
- **Diseases:** chronic lymphocytic leukemia (MONDO:0004948), Richter transformation (MONDO:0002083), histoplasmosis (MONDO:0018312)

## Full-text entities

- **Genes:** PTHLH (parathyroid hormone like hormone) [NCBI Gene 5744] {aka BDE2, HHM, PLP, PTHR, PTHRP}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, LOC102723407 (immunoglobulin heavy variable 4-38-2-like) [NCBI Gene 102723407] {aka IGHV4, IGHV4-30, IGHV4-38-2, IGHV4-39, IGHV4-b, IGVH4-39}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD7 (CD7 molecule) [NCBI Gene 924] {aka GP40, LEU-9, TP41, Tp40}, IGHV3-69-1 (immunoglobulin heavy variable 3-69-1 (pseudogene)) [NCBI Gene 28402] {aka IGHV3-H, IGHV3H}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, FUT4 (fucosyltransferase 4) [NCBI Gene 2526] {aka CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}, FCER2 (Fc epsilon receptor II) [NCBI Gene 2208] {aka BLAST-2, CD23, CD23A, CLEC4J, FCE2, FCErII}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** abdominal pain (MESH:D015746), polyuria (MESH:D011141), HRS (MESH:D020191), B symptoms (MESH:D006509), anorexia (MESH:D000855), IIIA (MESH:C566889), opportunistic infections (MESH:D009894), adenopathy (MESH:D000072281), Cancer (MESH:D009369), retroperitoneal lymphadenopathy (MESH:D012186), CLL (MESH:D015451), EBV infection (MESH:D020031), fibrosis (MESH:D005355), CDH (MESH:D006660), vomiting (MESH:D014839), granulomatous lymphadenitis (MESH:D008199), cervical lymphadenopathy (MESH:D002575), proptosis (MESH:D005094), cryptococcus infections (MESH:D003453), fever (MESH:D005334), hematologic malignancies (MESH:D019337), HL (MESH:D006689), fatigue (MESH:D005221), acute kidney injury (MESH:D058186), diarrhea (MESH:D003967), granulomatous disease (MESH:D006105), LAD (MESH:D008206), chronic musculoskeletal pain (MESH:D059352), splenomegaly (MESH:D013163), hypogammaglobulinemia (MESH:D000361), weight loss (MESH:D015431), hypercalcemia (MESH:D006934), joint pains (MESH:D018771), cough (MESH:D003371), infection (MESH:D007239), gastrointestinal intolerance (MESH:D005767), thrombocytopenia (MESH:D013921), transformation (MESH:D002472), immunodeficiency (MESH:D007153), cytopenias (MESH:D006402), viral infections (MESH:D014777), anemia (MESH:D000740), T-cell lymphoma (MESH:D016399), neuropathy (MESH:D009422), RT (MESH:C537025), infectious disease (MESH:D003141), fungal (MESH:D009181), tumor lysis syndrome (MESH:D015275), diffuse large B-cell lymphoma (MESH:D016403), lymphocytosis (MESH:D008218), 11.2 mg/dL (OMIM:615206), constipation (MESH:D003248), granulomas (MESH:D006099), Hodgkin or non-Hodgkin lymphoma (MESH:D008228), lymphoma (MESH:D008223), impaired kidney function (MESH:D007674), B cell lymphoma (MESH:D016393), multi-organ damage (MESH:D000092124)
- **Chemicals:** Venetoclax (MESH:C579720), dacarbazine (MESH:D003606), BR (MESH:D001966), voriconazole (MESH:D065819), Cyclophosphamide (MESH:D003520), bleomycin (MESH:D001761), Fludarabine (MESH:C024352), ABVD (MESH:C034632), Ibrutinib (MESH:C551803), FDG (MESH:D019788), bendamustine (MESH:D000069461), Amphotericin B (MESH:D000666), Rituximab (MESH:D000069283), 25-hydroxyvitamin D (MESH:C104450), Adriamycin (MESH:D004317), FCR (-), bisphosphonates (MESH:D004164), creatinine (MESH:D003404), calcium (MESH:D002118), 1,25-dihydroxyvitamin D (MESH:C097949), nivolumab (MESH:D000077594), fluconazole (MESH:D015725), Itraconazole (MESH:D017964)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Histoplasma capsulatum (species) [taxon 5037], Homo sapiens (human, species) [taxon 9606], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950534/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950534/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950534/full.md

---
Source: https://tomesphere.com/paper/PMC12950534